Aerobic Exercise Training Increases Circulating sRAGE in Adults With Type 2 Diabetes: Associations With Sheddase Regulation.

Diabetes Obes MetabJun 17, 2026 (epub)
Clinical ResearchEndocrinologyOpen access

Ryan K Perkins, Corey E Mazo, James Shadiow et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial investigated the impact of supervised aerobic exercise training (AET) on circulating sRAGE and sTLR4 in 33 sedentary adults with type 2 diabetes mellitus (T2DM). AET significantly increased circulating sRAGE concentrations, while sTLR4 levels remained unchanged. Additionally, AET improved cardiorespiratory fitness and metabolic health outcomes.

Key findings

  • AET increased circulating sRAGE concentrations during the intervention.
  • AET improved cardiorespiratory fitness and reduced body fat percentage.
  • Fructosamine concentrations decreased following AET.
  • Associations were found between changes in circulating sRAGE and aerobic fitness.

Why it matters

Understanding the effects of aerobic exercise on inflammatory markers like sRAGE can help clinicians develop effective lifestyle interventions for managing type 2 diabetes and its associated complications.

Source

PubMed · PMID 42310923Free full text on PubMed Central

Published in Diabetes Obes Metab. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.